Spatiotemporal GLP-1 and GIP receptor signaling and trafficking/recycling dynamics induced by selected receptor mono- and dual-agonists.
Mol Metab · 2021
Last updated 2026-05-28In a lab study, researchers compared how different GLP-1 and GIP drugs—including semaglutide, MAR709, and tirzepatide—affect cell signaling and receptor behavior. They found that MAR709 and tirzepatide produced similar maximum effects on cAMP production (a key step in cell signaling) but caused less receptor internalization than other drugs. The study also noted that MAR709 did not differ from GLP-1 mono-agonists in how it interacted with recycling endosomes, which help recycle receptors back to the cell surface.
AI summary of the abstract below.
| Journal | Mol Metab, 2021 |
|---|---|
| Citations | 77 |
| Relative citation ratio | 5.00 |
| NIH percentile | 92 |
| Molecules | — |
| Conditions studied | Type 2 Diabetes, Obesity |
Abstract
OBJECTIVE: We assessed the spatiotemporal GLP-1 and GIP receptor signaling, trafficking, and recycling dynamics of GIPR mono-agonists, GLP-1R mono-agonists including semaglutide, and GLP-1/GIP dual-agonists MAR709 and tirzepatide.
METHODS: Receptor G protein recruitment and internalization/trafficking dynamics were assessed using bioluminescence resonance energy transfer (BRET)-based technology and live-cell HILO microscopy.
RESULTS: Relative to native and acylated GLP-1 agonists, MAR709 and tirzepatide showed preserved maximal cAMP production despite partial Gα recruitment paralleled by diminished ligand-induced receptor internalization at both target receptors. Despite MAR709's lower internalization rate, GLP-1R co-localization with Rab11-associated recycling endosomes was not different between MAR709 and GLP-1R specific mono-agonists.
CONCLUSIONS: Our data indicated that MAR709 and tirzepatide induce unique spatiotemporal GLP-1 and GIP receptor signaling, trafficking, and recycling dynamics relative to native peptides, semaglutide, and matched mono-agonist controls. These findings support the hypothesis that the structure of GLP-1/GIP dual-agonists confer a biased agonism that, in addition to its influence on intracellular signaling, uniquely modulates receptor trafficking.
Verbatim abstract via PubMed 33556643 ↗